Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by Evercore ISI in a research report issued to clients and investors on Thursday, AnalystRatings.com reports. They presently have a $200.00 price objective on the biotechnology company’s stock. Evercore ISI’s target price points to a potential upside of 58.59% from the stock’s current price.
The analysts wrote, “We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well.””
A number of other analysts also recently weighed in on the company. BidaskClub downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd. Morgan Stanley boosted their price target on Sarepta Therapeutics from $165.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. BTIG Research set a $190.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Wednesday, April 17th. Royal Bank of Canada boosted their price target on Sarepta Therapeutics from $188.00 to $220.00 and gave the stock an “outperform” rating in a report on Monday, July 1st. Finally, HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Monday, June 17th. Two analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $208.29.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($2.66). The company had revenue of $94.67 million for the quarter, compared to the consensus estimate of $91.05 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The business’s revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.67) earnings per share. As a group, sell-side analysts forecast that Sarepta Therapeutics will post -4.04 EPS for the current fiscal year.
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $120.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director now owns 21,717 shares of the company’s stock, valued at approximately $2,606,040. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.60% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Columbus Circle Investors increased its stake in shares of Sarepta Therapeutics by 57.7% in the first quarter. Columbus Circle Investors now owns 392,243 shares of the biotechnology company’s stock valued at $46,751,000 after buying an additional 143,552 shares during the period. Wealthstreet Investment Advisors LLC increased its stake in shares of Sarepta Therapeutics by 147.9% in the first quarter. Wealthstreet Investment Advisors LLC now owns 6,520 shares of the biotechnology company’s stock valued at $777,000 after buying an additional 3,890 shares during the period. Cooper Haims Advisors LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $953,000. Quadrant Capital Group LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $51,000. Finally, Boston Advisors LLC increased its stake in shares of Sarepta Therapeutics by 43.4% in the first quarter. Boston Advisors LLC now owns 11,255 shares of the biotechnology company’s stock valued at $1,341,000 after buying an additional 3,405 shares during the period. 94.72% of the stock is owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: Preferred Stock
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.